dc.contributor.author | Skarphedinsson, Gudmundur Águst | |
dc.contributor.author | Weidle, Bernhard | |
dc.contributor.author | Ivarsson, Tord | |
dc.date.accessioned | 2017-12-18T12:45:29Z | |
dc.date.available | 2017-12-18T12:45:29Z | |
dc.date.created | 2015-10-08T09:26:46Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | Journal of child and adolescent psychopharmacology. 2015, 25 (7), 574-579. | nb_NO |
dc.identifier.issn | 1044-5463 | |
dc.identifier.uri | http://hdl.handle.net/11250/2472507 | |
dc.description.abstract | Objective: The purpose of this study was to investigate the effect of sertraline (SRT) in children and adolescents with obsessive-compulsive disorder (OCD) who did not respond to two consecutive courses of cognitive-behavior therapy (CBT). Methods: Observational study with 11 participants (males, n=6), 7–17 years of age with Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) primary OCD. All had received 14 plus 10 sessions of CBT over the course of 218–532 days (mean=342.2, SD=85.5). Outcome measures were mean reduction of the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) total score and adequate clinical response (CY-BOCS<16). All participants received SRT (maximum dose 200 mg/day). The study was a part of the Nordic Long-Term OCD Treatment Study (NordLOTS). Results: Participants were treated with SRT over 72–300 days (mean=164.2, SD=68.3). The mean CY-BOCS score was reduced from 21.5 (SD=2.6) to 17.5 (SD=3.3). Only three participants obtained adequate clinical response (27.2%), and only two obtained >25% CY-BOCS total score reduction (close to 50%). Conclusions: A clinical response in approximately one third of the participants suggests that SRT treatment might be beneficial to a minority of patients who have consistently failed CBT. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | Mary Ann Liebert | nb_NO |
dc.title | Sertraline treatment of nonresponders to extended cognitive-behavior therapy in pediatric obsessive-compulsive disorder | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.description.version | acceptedVersion | nb_NO |
dc.source.pagenumber | 574-579 | nb_NO |
dc.source.volume | 25 | nb_NO |
dc.source.journal | Journal of child and adolescent psychopharmacology | nb_NO |
dc.source.issue | 7 | nb_NO |
dc.identifier.doi | 10.1089/cap.2015.0041 | |
dc.identifier.cristin | 1279150 | |
dc.relation.project | Norges forskningsråd: 196291 | nb_NO |
dc.description.localcode | This is the authors' manuscript to the article (Preprint). Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/10.1089/cap.2015.0041 | nb_NO |
cristin.unitcode | 194,65,35,5 | |
cristin.unitname | RKBU Midt-Norge - Regionalt kunnskapssenter for barn og unge - psykisk helse og barnevern | |
cristin.ispublished | true | |
cristin.fulltext | preprint | |
cristin.qualitycode | 1 | |